A 38-year-old female patient is 4 hours post-op following laparoscopic cholecystectomy. She is on intravenous PCA with fentanyl (10 mcg bolus, 6-minute lockout, 4-hour limit 100 mcg). She complains of nausea and has vomited once. She has pressed the PCA button only 3 times in the last hour. Her vital signs are: BP 118/76, HR 82, RR 14, SpO₂ 97% on room air. She is drowsy but arousable. What is the most appropriate next step in management?

Explanation

## Management of Opioid-Induced Nausea in PCA ### Clinical Assessment The patient has: - **Adequate analgesia:** Only 3 button presses in 1 hour (low demand indicates pain is controlled) - **Opioid-induced nausea:** Single episode of vomiting, likely dose-related - **Safe respiratory status:** RR 14, SpO₂ 97%, arousable - **Stable hemodynamics:** BP and HR normal **Key Point:** Nausea with infrequent PCA demands indicates opioid toxicity (too much drug), NOT inadequate analgesia. The solution is antiemetic therapy, NOT dose reduction or discontinuation. ### Why Ondansetron Is the Correct Choice 1. **5-HT₃ antagonist:** Highly effective for opioid-induced nausea and vomiting (OINV) 2. **Preserves analgesia:** Does not reduce opioid dose; patient retains pain control 3. **Rapid onset:** Works within 5–10 minutes IV 4. **Safe profile:** No significant drug interactions with fentanyl 5. **Standard of care:** First-line antiemetic for OINV in post-operative settings ### Comparison of Antiemetic Options for OINV | Agent | Mechanism | Efficacy | Onset | Notes | |-------|-----------|----------|-------|-------| | **Ondansetron** | 5-HT₃ antagonist | Excellent | 5–10 min | First-line; no respiratory depression | | Metoclopramide | D₂ antagonist + prokinetic | Moderate | 10–15 min | Less effective for opioid OINV; risk of tardive dyskinesia | | Dexamethasone | Anti-inflammatory | Moderate | 30–60 min | Slower onset; better for delayed OINV | | Droperidol | D₂ antagonist | Good | 5–10 min | Risk of QT prolongation; less commonly used now | | Scopolamine | Anticholinergic | Moderate | Variable | Transdermal; slower onset | **High-Yield:** Opioid-induced nausea with infrequent PCA demands = **antiemetic therapy**, not dose reduction. Conversely, nausea with frequent demands = consider dose reduction. ### Why Other Options Are Incorrect ```mermaid flowchart TD A[Patient on PCA with nausea]:::outcome B{PCA demand frequency?}:::decision A --> B B -->|Frequent demands| C[Nausea = inadequate analgesia]:::action B -->|Infrequent demands| D[Nausea = opioid toxicity]:::action C --> E[Increase bolus dose]:::action D --> F[Add antiemetic: ondansetron 4 mg IV]:::action F --> G[Continue PCA unchanged]:::action ``` **Clinical Pearl:** The key discriminator is PCA demand frequency. Frequent button presses + nausea = pain breakthrough + toxicity (increase dose + antiemetic). Infrequent presses + nausea = pure toxicity (antiemetic only, do NOT increase dose). [cite:Miller's Anesthesia 8e Ch 33; Park 26e Ch 3]